Phosphoproteomics identifies driver tyrosine kinases in sarcoma cell lines and tumors

Cancer Research

Volumn 72, Issue 10, 2012, Pages 2501-2511

  Bai, Yun ^a   Li, Jiannong ^a   Fang, Bin ^a   Edwards, Arthur ^a   Zhang, Guolin ^a   Bui, Marilyn ^a   Eschrich, Steven ^a   Altiok, Soner ^a   Koomen, John ^a   Haura, Eric B ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [4 METHYL 2 (2 OXO 3 INDOLINYLMETHYLIDENYL) 3 PYRROLYL]PROPIONIC ACID; 5 (2,6 DICHLOROBENZYLSULFONYL) 3 [3,5 DIMETHYL 4 [2 (1 PYRROLIDINYLMETHYL) 1 PYRROLIDINYLCARBONYL] 1H PYRROL 2 YLMETHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; DASATINIB; ENZYME ANTIBODY; ERLOTINIB; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 2; IMATINIB; INSULIN RECEPTOR; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE 3; OSI 868; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN AXL; PROTEIN DDR1; PROTEIN DDR2; PROTEIN EPHB4; PROTEIN FAK; PROTEIN KINASE; PROTEIN KINASE LYN; PROTEIN SRC; PROTEIN TYR2; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SCATTER FACTOR RECEPTOR; SOMATOMEDIN C; SOMATOMEDIN RECEPTOR; UNCLASSIFIED DRUG; VANDETANIB;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL GROWTH; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME PHOSPHORYLATION; ENZYME PURIFICATION; HUMAN; HUMAN TISSUE; LIQUID CHROMATOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; RHABDOMYOSARCOMA; RNA INTERFERENCE; SARCOMA; SARCOMA CELL; SIGNAL TRANSDUCTION; TANDEM MASS SPECTROMETRY;

CELL LINE, TUMOR; HUMANS; PHOSPHORYLATION; PHOSPHOTYROSINE; PROTEIN-TYROSINE KINASES; PROTEOMICS; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; RNA, SMALL INTERFERING; SARCOMA; SIGNAL TRANSDUCTION;

EID: 84861158485     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-3015     Document Type: Article

References (36)

1. Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001;344:1052-6. (Pubitemid 32267975)
2. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006;368: 1329-38. (Pubitemid 44528723)
3. Crose LE, Linardic CM. Receptor tyrosine kinases as therapeutic targets in rhabdomyosarcoma. Sarcoma 2011;2011:756982.
4. Shor AC, Agresta SV, D'Amato GZ, Sondak VK. Therapeutic potential of directed tyrosine kinase inhibitor therapy in sarcomas. Cancer Control 2008;15:47-54. (Pubitemid 351481991)
5. Ray-Coquard I, Le Cesne A, Whelan JS, Schoffski P, Bui BN, Verweij J, et al. A phase II study of gefitinib for patients with advanced HER-1 expressing synovial sarcoma refractory to doxorubicin-containing regimens. Oncologist 2008;13:467-73. (Pubitemid 351679928)
6. Stommel JM, Kimmelman AC, Ying H, Nabioullin R, Ponugoti AH, Wiedemeyer R, et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 2007;318:287-90. (Pubitemid 47574858)
7. Jensen ON. Interpreting the protein language using proteomics. Nat Rev Mol Cell Biol 2006;7:391-403. (Pubitemid 44050093)
8. Pawson T, Scott JD. Signaling through scaffold, anchoring, and adaptor proteins. Science 1997;278:2075-80. (Pubitemid 28028310)
9. Bose R, Molina H, Patterson AS, Bitok JK, Periaswamy B, Bader JS, et al. Phosphoproteomic analysis of Her2/neu signaling and inhibition. Proc Natl Acad Sci U S A 2006;103:9773-8. (Pubitemid 43993573)
10. Goss VL, Lee KA, Moritz A, Nardone J, Spek EJ, MacNeill J, et al. A common phosphotyrosine signature for the Bcr-Abl kinase. Blood 2006;107:4888-97. (Pubitemid 43882642)
11. Rush J, Moritz A, Lee KA, Guo A, Goss VL, Spek EJ, et al. Immunoaffinity profiling of tyrosine phosphorylation in cancer cells. Nat Biotechnol 2005;23:94-101. (Pubitemid 41724631)
12. Li J, Rix U, Fang B, Bai Y, Edwards A, Colinge J, et al. A chemical and phosphoproteomic characterization of dasatinib action in lung cancer. Nat Chem Biol 2010;6:291-9.
13. Walters DK, Goss VL, Stoffregen EP, Gu TL, Lee K, Nardone J, et al. Phosphoproteomic analysis of AML cell lines identifies leukemic oncogenes. Leuk Res 2006;30:1097-104. (Pubitemid 44055977)
14. Walters DK, Mercher T, Gu TL, O'Hare T, Tyner JW, Loriaux M, et al. Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell 2006;10:65-75.
15. Kreahling JM, Gemmer JY, Reed D, Letson D, Bui M, Altiok S. MK1775, a selective Wee1 inhibitor, shows single-agent antitumor activity against sarcoma cells. Mol Cancer Ther 2012;11:174-82.
16. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science 2002;298:1912-34. (Pubitemid 35425239)
17. Fabian MA, Biggs WH 3rd, Treiber DK, Atteridge CE, Azimioara MD, Benedetti MG, et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 2005;23:329-36. (Pubitemid 41094421)
18. Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT, et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008;26:127-32.
19. Carter TA, Wodicka LM, Shah NP, Velasco AM, Fabian MA, Treiber DK, et al. Inhibition of drug-resistant mutants of ABL, KIT, andEGFreceptor kinases. Proc Natl Acad Sci U S A 2005;102:11011-6. (Pubitemid 41105984)
20. Hantschel O, Rix U, Superti-Furga G. Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib. Leuk Lymphoma 2008; 49:615-9. (Pubitemid 351517198)
21. Li J, Rix U, Fang B, Bai Y, Edwards A, Colinge J, et al. A chemical and phosphoproteomic characterization of dasatinib action in lung cancer. Nat Chem Biol 2010;6:291-9.
22. Remsing Rix LL, Rix U, Colinge J, Hantschel O, Bennett KL, Stranzl T, et al. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. Leukemia 2009;23:477-85.
23. Rix U, Hantschel O, Durnberger G, Remsing Rix LL, Planyavsky M, Fernbach NV, et al. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 2007;110:4055-63. (Pubitemid 350248462)
24. McDermott U, Ames RY, Iafrate AJ, Maheswaran S, Stubbs H, Greninger P, et al. Ligand-dependent platelet-derived growth factor receptor (PDGFR)-alpha activation sensitizes rare lung cancer and sarcoma cells to PDGFR kinase inhibitors. Cancer Res 2009;69: 3937-46.
25. Armistead PM, Salganick J, Roh JS, Steinert DM, Patel S, Munsell M, et al. Expression of receptor tyrosine kinases and apoptotic molecules in rhabdomyosarcoma: correlation with overall survival in 105 patients. Cancer 2007;110:2293-303. (Pubitemid 350100752)
26. Taniguchi E, Nishijo K, McCleish AT, Michalek JE, Grayson MH, Infante AJ, et al. PDGFR-A is a therapeutic target in alveolar rhabdomyosarcoma. Oncogene 2008;27:6550-60.
27. Park M, Dean M, Cooper CS, Schmidt M, O'Brien SJ, Blair DG, et al. Mechanism of met oncogene activation. Cell 1986;45:895-904. (Pubitemid 16083694)
28. Carboni JM, Wittman M, Yang Z, Lee F, Greer A, Hurlburt W, et al.BMS- 754807, a small molecule inhibitor of insulin-like growth factor-1R/IR. Mol Cancer Ther 2009;8:3341-9.
29. Buck E, Gokhale PC, Koujak S, Brown E, Eyzaguirre A, Tao N, et al. Compensatory insulin receptor (IR) activation on inhibition of insulinlike growth factor-1 receptor (IGF-1R): rationale for cotargeting IGF-1R and IR in cancer. Mol Cancer Ther 2010;9:2652-64.
30. Olmos D, Martins AS, Jones RL, Alam S, Scurr M, Judson IR. Targeting the insulin-like growth factor 1 receptor in Ewing's Sarcoma: reality and expectations. Sarcoma 2011;2011:402508.
31. Juergens H, Daw NC, Geoerger B, Ferrari S, Villarroel M, Aerts I, et al. Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma. J Clin Oncol 2011;29:4534-40.
32. Pappo AS, Patel SR, Crowley J, Reinke DK, Kuenkele KP, Chawla SP, et al. R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study. J Clin Oncol 2011;29:4541-7.
33. Del Rosario AM, White FM. Quantifying oncogenic phosphotyrosine signaling networks through systems biology. Curr Opin Genet Dev 2010;20:23-30.
34. Baselga J. Targeting tyrosine kinases in cancer: the second wave. Science 2006;312:1175-8. (Pubitemid 43801135)
35. Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007;131:1190-203. (Pubitemid 350235027)
36. Walters DK, Goss VL, Stoffregen EP, Gu TL, Lee K, Nardone J, et al. Phosphoproteomic analysis of AML cell lines identifies leukemic oncogenes. Leukemia Res 2006;30:1097-104. (Pubitemid 44055977)